0001493152-24-011110.txt : 20240325 0001493152-24-011110.hdr.sgml : 20240325 20240325140056 ACCESSION NUMBER: 0001493152-24-011110 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240325 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240325 DATE AS OF CHANGE: 20240325 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DAXOR CORP CENTRAL INDEX KEY: 0000027367 ORGANIZATION NAME: IRS NUMBER: 132682108 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 811-22684 FILM NUMBER: 24778440 BUSINESS ADDRESS: STREET 1: 350 FIFTH AVENUE STREET 2: SUITE 4740 CITY: NEW YORK STATE: NY ZIP: 10118 BUSINESS PHONE: 212-330-8500 MAIL ADDRESS: STREET 1: 350 5TH AVENUE STREET 2: SUITE 4740 CITY: NEW YORK STATE: NY ZIP: 10118 FORMER COMPANY: FORMER CONFORMED NAME: IDANT CORP DATE OF NAME CHANGE: 19730823 8-K 1 form8-k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) March 25, 2024

Daxor Corporation

(Exact name of registrant as specified in its charter)

New York	811-22684	13-2682108
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

109 Meco Lane, Oak Ridge, TN		37830
(Address of principal executive offices)		(Zip Code)

212-330-8500

Registrant’s telephone number, including area code

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR

240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock $0.01 par value		DXR		Nasdaq

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Item 8.01 – Other Events

On March 25, 2024 Daxor Corporation announced it has entered into a definitive agreement to acquire exclusive and worldwide rights and intellectual property to manufacture from its existing supplier for Volumex and Megatope from privately-held Iso-Tex Diagnostics, Inc. Daxor has also acquired the exclusive rights to Glofil, a drug that measures glomerular filtration rate (GFR), which Iso-Tex has been selling directly to its customer base.

The press release issued is attached to this filing as Exhibit 99.1

Item 9.01 Exhibits

(d)	Exhibits. The following exhibit is filed with this Current Report on Form 8-K:

No.		Description
99.1		Press release dated March 25, 2024 – Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics
104		Cover Page Interactive Data File (embedded within the Inline XBRL document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

	DAXOR CORPORATION
	(Registrant)

Date: March 25, 2024	By:	/s/ Robert J. Michel
	Name:	Robert J. Michel
	Title:	Chief Financial Officer

EX-99.1 2 ex99-1.htm

Exhibit 99.1

Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics

Expected to Improve Margins and Increase Revenue Streams

Oak Ridge, TN – March 25, 2024 -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it has entered into a definitive agreement to acquire exclusive and worldwide rights and intellectual property to manufacture from its existing supplier for Volumex and Megatope from privately-held Iso-Tex Diagnostics, Inc. Daxor has also acquired the exclusive rights to Glofil, a drug that measures glomerular filtration rate (GFR), which Iso-Tex has been selling directly to its customer base.

Daxor projects the acquisitions to be cash flow positive and accretive to earnings immediately upon transfer of the manufacturing. This is due to the embedded revenue streams of the drugs and significantly higher margins that will be achieved with internalized production.

“Bringing the manufacturing of these radiopharmaceutical diagnostics in-house at our Oak Ridge facility is a game-changer for Daxor that will substantially increase our margins on blood volume analysis (BVA) test kits as we scale up,” said Michael Feldschuh, President and CEO of Daxor. “Acquiring Glofil gives us a new product to cross-sell into our growing customer base.”

“Glofil, a trusted GFR diagnostic, shares a user base that overlaps with Daxor’s core hospital customers. Adding Glofil allows Daxor to offer a compelling combined product suite for measuring both blood volume and kidney function creating an additional revenue stream for the company,” said Senior Vice President of Commercialization and Customer Experience, Jean Oertel.

The deals have been structured with seller-provided financing on favorable terms. No payments will come due until manufacturing is fully transitioned to Daxor over the next 6-9 months. The total transaction value will then be paid in monthly installments over two years from that point, with payments anticipated to be supported by the revenue from Glofil and cost-savings from in-house manufacture of BVA test kits.

The transaction is subject to customary conditions, including receipt of applicable regulatory approvals.

About Iso-Tex Diagnostics, Inc.

Founded in 1975 by Tom Maloney, Iso-Tex manufactures radiopharmaceuticals for diagnostic and therapeutic applications for Daxor and other customers. Iso-Tex is headquartered in Pearland, Texas.

About Daxor Corporation

Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100^® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor’s mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:

Bret Shapiro

Sr. Managing Partner, CORE IR

1-516-222-2560

brets@coreir.com

GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 dxr-20240325.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 dxr-20240325_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 dxr-20240325_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT

Cover	Mar. 25, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Mar. 25, 2024
Entity File Number	811-22684
Entity Registrant Name	Daxor Corporation
Entity Central Index Key	0000027367
Entity Tax Identification Number	13-2682108
Entity Incorporation, State or Country Code	NY
Entity Address, Address Line One	109 Meco Lane
Entity Address, City or Town	Oak Ridge
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37830
City Area Code	212
Local Phone Number	330-8500
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock $0.01 par value
Trading Symbol	DXR
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

5BJQ"(6,P$ "(" / " M 4(0 !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " :<'E8)!Z;HJT #X M 0 &@ @ &B$0 >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E M;'-02P$"% ,4 " :<'E899!YDAD! #/ P $P @ &' L$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" #1$P ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://daxor.com/role/Cover Cover Cover 1 false false All Reports Book All Reports dxr-20240325.xsd dxr-20240325_lab.xml dxr-20240325_pre.xml form8-k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "DXR", "nsuri": "http://daxor.com/20240325", "dts": { "schema": { "local": [ "dxr-20240325.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "dxr-20240325_lab.xml" ] }, "presentationLink": { "local": [ "dxr-20240325_pre.xml" ] }, "inline": { "local": [ "form8-k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://daxor.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-03-25", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-25", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001493152-24-011110-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-011110-xbrl.zip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form8-k_htm.xml IDEA: XBRL DOCUMENT 0000027367 2024-03-25 2024-03-25 iso4217:USD shares iso4217:USD shares false 0000027367 8-K 2024-03-25 Daxor Corporation NY 811-22684 13-2682108 109 Meco Lane Oak Ridge TN 37830 212 330-8500 false false false false Common Stock $0.01 par value DXR NASDAQ false